Medtronic PLC (NYSE: MDT) Q3 2020 Earnings Call Transcript

Medtronic PLC  (NYSE: MDT) Q3 2020 Earnings Conference Call
Feb. 18, 2020

Corporate Participants:

Ryan Weispfenning — Vice President, Head of Investor Relations

Omar Ishrak — Chairman and Chief Executive Officer

Karen L. Parkhill — Executive Vice President and Chief Financial Officer

Geoffrey S. Martha — President

Michael J. Coyle — Executive Vice President and Group President, Cardiac and Vascular Group

Robert White — Executive Vice President and President, Minimally Invasive Therapies Group

Brett Wall — Executive Vice President and President, Restorative Therapies Group

Analysts:

Bob Hopkins — Bank of America — Analyst

David Lewis — Morgan Stanley — Analyst

Robbie Marcus — JP Morgan — Analyst

Vijay Kumar — Evercore — Analyst

Matt Taylor — UBS — Analyst

Kristen Stewart — Barclays — Analyst

Kaila Krum — SunTrust — Analyst

Larry Biegelsen — Wells Fargo — Analyst

Matt Miksic — Credit Suisse — Analyst

Chris Pasquale — Guggenheim — Analyst

Pito Chickering — Deutsche Bank — Analyst

Matthew O’Brien — Piper Sandler — Analyst

Josh Jennings — Cowen — Analyst

Presentation:

Operator

Ladies and gentlemen, thank you for standing by. And welcome to the Medtronic Third Quarter Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speakers’ presentation, there will be a question-and-answer session. [Operator Instructions] I would like to hand the conference over to Ryan Weispfenning, Vice President, Head of Investor Relations. Please go ahead, sir.

Ryan Weispfenning — Vice President, Head of Investor Relations

Thank you. Good morning and welcome to Medtronic’s fiscal year 2020 third quarter conference call and webcast. During the next hour, Omar Ishrak, Medtronic’s Chairman and Chief Executive Officer; and Karen Parkhill, Medtronic’s Chief Financial Officer and Geoff Martha, Medtronic President will provide comments on the results of our third quarter, which ended on January 24th, 2020. After our prepared remarks, we’ll be happy to take your questions. First, a few logistical comments. Earlier this morning, we issued a press release containing our financial statements and the revenue by division summary. We also issued an earnings presentation that provides additional details on our performance and outlook.

During today’s earnings call, many of the statements made may be considered forward-looking statements and actual results may differ materially from those projected in any forward-looking statement. Additional information concerning factors that could cause actual results to differ is contained in our periodic reports and other filings that we make with the SEC and we do not undertake to update any forward-looking statements. For this call, unless we say otherwise, rates and ranges are given on a constant currency basis, which compares to the third quarter of fiscal year 2019 after adjusting for foreign currency. References to organic revenue growth, exclude the impact of our Titan Spine acquisition and currency.

Reconciliations of all non-GAAP financial measures can be found in the attachment to our earnings press release or on our website at investorrelations.medtronic.com. Finally, our EPS guidance does not include any charges or gains that would be reported as non-GAAP adjustments to earnings during the fiscal year.

With that, I’m now pleased to turn the call over to Medtronic Chairman and Chief Executive Officer, Omar Ishrak. Omar?

Omar Ishrak — Chairman and Chief Executive Officer

Thank you, Ryan, and thank you to everyone for joining us. This morning, we reported results for the third fiscal quarter, Revenue growth was light this quarter, reflecting a series of largely transient issues which I’ll walk you through in a minute.

The good news however is that this was more than offset by 90 basis points of operating margin expansion well ahead of our expectations resulting in strong EPS and free cash flow growth, both ahead of plan. Importantly, despite the top line shortfall this quarter, our Q4 outlook is unchanged, as we expect significant revenue growth acceleration excluding any impact from the coronavirus. Q3 revenue grew 2.9% in constant currency and 2.6% organic. Revenue growth fell short of our expectations, driven in part by customers curbing their purchasing ahead of our new product launches, principally in CVG and RTG. In MITG, we upgraded the group’s ERP system in the U.S. and Canada to our company-wide system, resulting in a temporary slowdown in our ability to supply customers, which in some cases resulted in loss procedures and lasted longer in the quarter than we anticipated.

That upgrade is now complete. And as of early this quarter we’re in the process of returning to full supply. All of these items led to our quarterly revenue underperformance. We weren’t able to offset these issues, given that many of them emerged late in the quarter. I’m not happy with this top line performance and we are focused on quickly addressing the dynamics that led to this result. Geoff will provide a little more color on this later on the call. Looking down the P&L, we drove significant operating leverage despite the softer top line. Our adjusted operating margin expanded 90 basis points as we continue to see the benefits of our enterprise excellence initiatives, particularly on the SG&A line.

We also had strong financial leverage, driven in part by the debt refinancing that we completed earlier this fiscal year. This resulted in adjusted EPS of a $1.44 which was $0.06 above the midpoint of our guidance and up 11.6% year-over-year. Let’s take a look now at the drivers for our group performances, starting with our Restorative Therapies Group, which grew 3.6% organic this quarter. RTG’s performance was affected by customer buying patterns in BMP and the continued market slowdown and slide share loss in Pain Stim ahead of our DTM therapy launch.

On an organic basis, our overall spine division was flat this quarter, reflecting customer drawdown of infuse inventory. Despite this, our Core Spine business grew 2% both globally and in the U.S. In addition when you include sales of enabling technology sold by our Brain Therapies division, which is how our competitors report, Core Spine grew 5% organically both globally and in the U.S. well above market. Our surgical synergy strategy is resulting in increased sales of our Core Spine implants, driven by surgeon’s use of our capital equipment, in particular our Mazor robot. It is also benefiting our Brain Therapies division, which sells the capital equipment used in spine surgery.

Brain Therapies delivered another above market quarter of 9.2% growth. In neurosurgery, which grew low double-digits, we had strong growth in Mazor robotics where we are meaningfully outpacing the competition, as well as in StealthStation navigation, O-arm imaging and our new Midas Rex MR8 systems. In Brain Therapies, our market-leading Neurovascular business had another strong quarter with mid teens growth driven by mid 20s growth in ischemic stroke and strong adoption of our Solitaire X stent retriever, Riptide Aspiration System and React catheters. In pain therapies, the pain Stim market had another sluggish quarter and we had some slight share loss ahead of the launch of the Stimgenics DTM therapy on our Intellis platform.

We’re excited about the response we received from physicians and the broader SCS community following the acquisition announcement and Stimgenics data presentation last month at NANS as well as on our nine year battery warranty on Intellis. We continue to be optimistic about the outlook for the Pain Stim market and have begun training physicians on the DTM waveform. Our Minimally Invasive Therapies Group grew 3.2% organic, including flat results in the U.S. MITGs performance this quarter was affected by the upgrade of its ERP system in the U.S. and Canada which caused some temporary slowdown in our ability to supply customers with the full breadth of our products and in some cases resulted in loss procedures. This was however a transient issue.

The ERP upgrade is now complete and the related supply slowdown are behind us as of this month. Within MITG, our Surgical Innovations Division grew 3.6% this quarter, driven by our Advanced Surgical business, particularly in Advanced Energy, which grew in the high single digits on strength in our LigaSure franchise and sales of our Valleylab FT10 energy platform. Respiratory, GI and renal division grew 2.2%, driven by low double digit growth in our GI Solutions business and high single digit growth in pulse oximetry sensors and advanced parameter sensors. In our Cardiac and Vascular group we grew 1.8% this quarter, which was below our expectations, due in part to customers holding back their purchasing ahead of new product launches in CRHF.

We saw high single digit declines in our High Power business as customer’s awaited approval of our Cobalt and Crome devices which have launched this month in Europe and are expected to launch in the U.S. during Q1. In heart failure, although our LVAD business has anniversaried the headwinds we faced over the past year, the business declined in the low single digits and hasn’t returned to the growth levels we were expecting. The other driver of our below expectation CVG performance was our U.S. TAVR business, which grew 13% this quarter below the market growth rate. While the TAVR market has been rapidly expanding, we currently have fully experienced field support coverage in a little more than two thirds of the approximately 700 U.S. centers performing TAVR.

We began aggressively hiring and training new field personnel months ago. However, our data shows that its taking longer than expected for our new reps to reach full productivity. We plan to certify an additional 70 field personnel by the end of this fiscal year. We expect our US TAVR performance to improve relative to the market going forward, as our expanded field organization reaches full productivity and we focus the market on the hemodynamic benefits of Evolut PRO+ platform and the launch of our new Confida sheath. Outside the US, our TAVR market share grew modestly in Q3.

Our pacing business grew in the high single digits, well above the market, driven by our exclusive Micra leadless pacemaker and AZURE family of conventional pacemakers. We announced the Micra AV approval in the last week of our quarter and are excited about its growth potential, as it expands the Micra target population from 15% to 55% of pacemaker patients. While we did not have revenue from Micra AV in the third quarter, we are already seeing strong interest in early adoption of this new technology in the fourth quarter. In diabetes we grew 0.8%, slightly ahead of expectations.

Our U.S. business declined in the low double digits which is anticipated and resulted from competitor challenges, while we await our new products. We’re seeing strong enrollment in our Next Tech Pathway program, which allows purchasers of the MiniMed 670G to upgrade for free to our next-generation pump when launched. Keep in mind that as a result of this program we are currently deferring a portion of the revenue of our pump sales, which we will recognize when patients trade in their 670G for the next generation pump.

In markets outside the United States which represents just under half of our diabetes revenue, we had solid mid-teens growth driven by the continued adoption of the MiniMed 670G. This demand is not only driving strong growth in our installed base. It is also resulting in double-digit growth in recurring revenue from CGM and other consumables. Now turning to emerging markets which represented 17% of our revenue. In Q3, we grew emerging markets 14% with contributions from geographies around the globe. China grew 14%, as is Southeast Asia and Eastern Europe grew 16% which included 39% growth in Russia.

In addition, South Asia grew 13%, as did the Middle East and Africa. And Latin America grew 12%. We continue to drive strong growth in these markets as we optimize the distribution channel and, in certain markets, localize R&D and manufacturing. Regarding the coronavirus, our top concern is the health and well-being of our employees in China and across the globe. We have activated response teams in China, the Asia Pacific region and globally, and we remain vigilant in monitoring the virus and taking action as necessary. All of our manufacturing operations are up and running in China. We’re committed to helping the Chinese government and Chinese physicians address this crisis.

As the Chinese healthcare system is focused on containing the spread of the virus, hospitals in China have experienced a slowing of medical device procedure rates, and we are seeing procedure delays. We do expect this to have a negative impact on our fourth-quarter financial results. But given the fluidity of this situation, the duration and magnitude of the impact are difficult to quantify at this time. Now turning to our product pipeline. As we look forward, we’re excited about what lies ahead as the investments we’ve made in our product pipeline begin to pay off by accelerating our revenue growth and creating value for our shareholders. We have recently received approval or launched a number of new products that we expect to contribute to our growth going forward.

I mentioned earlier the U.S. approval of our Micra AV pacemaker and the launch that is now under way. We also received U.S. approval for our IN.PACT Admiral AV fistula indication which expands the market potential of our drug-coated balloons. We received U.S. approval and are launching our Stealth Autoguide cranial robotic system. In Europe, we recently received CE mark approval for our cobalt and crome portfolio of BlueSync-enabled high-power devices, our InterStim Micro rechargeable implantable sacral neuromodulation device and InterStim SureScan MRI leads as well as our Percept PC DBS device with BrainSense technology. And over the next few quarters, we expect approval and launch of a number of additional new products.

We expect U.S. approval of the cobalt and crome high-power devices, Reveal LINQ 2.0 insertable cardiac monitor, InterStim Micro and InterStim SureScan MRI leads and our Percept PC DBS device. We’re also expecting European launch of the MiniMed 780G and our DiamondTemp ablation catheter. Regarding our MiniMed 780G in the U.S., we intend to file our adult clinical data with the FDA in March which will push expected approval beyond the fiscal year-end. In pain stim, we unveiled DTM spinal cord stim last month at the NANS conference and are now training our field force on this novel waveform, with an expected limited launch in Q4 and full launch in Q1. In MITG, we continue to make progress in our soft tissue robotics program.

Last week, we announced the acquisition of Digital Surgery, a pioneer in artificial intelligence and analytics for surgery. They lead the industry with their unique Touch Surgery ecosystem of products including AI that identify surgical steps and instrumentation. These products can be leveraged to provide insight into the procedure time, cost and process to improve surgical care. We’re excited about utilizing the strength and capability of Digital Surgery to advance our minimally invasive and robotic surgery platforms. We also have a number of important upcoming data presentations, starting with use case data under extreme conditions for our advanced hybrid closed-loop algorithm at ATTD later this week.

Next month, ACC will be a big conference for us. Data from our off med renal denervation pivotal trial will be presented as well as data for both low-risk bicuspid and leaflet immobility for our TAVR program. Also, we will share risk stratification data for our TYRX anti-infection product. And finally, in June, at ADA, we expect to present the U.S. pivotal data for our MiniMed 780G advanced hybrid closed-loop system. This is just some of the near-term highlights from our pipeline. Importantly, we’re continuing to invest in building out a robust long-term pipeline of continuous innovation, invention and disruption.

I mentioned earlier that we expect significant acceleration in our fourth-quarter revenue growth driven in part by our pipeline and excluding the impact of the coronavirus. And as we look to FY ’21, we expect our top-line momentum to continue as we get the increasing benefit of the FY ’20 product launches as well as the products slated to launch next fiscal year.

With that, let me now ask Karen to take you through a discussion of our third-quarter financials and forward outlook. Karen?

Karen L. Parkhill — Executive Vice President and Chief Financial Officer

Thank you. As Omar mentioned, we delivered third-quarter organic revenue growth of 2.6%, and adjusted EPS was $1.44, growing 11.6%. We ultimately came in $0.06 above the midpoint of our guidance and would attribute $0.02 to better-than-expected foreign exchange and $0.04 to operational outperformance including tax.

Our adjusted gross margin was 69.7%, down year over year due in part to increased China tariffs. We more than offset that decline with strong operating leverage as we continue to implement and drive efficiencies and improvements across the company while, at the same time, making investments ahead of upcoming product launches. This led to an adjusted operating margin improvement of 90 basis points or 70 basis points excluding the impact of currency.

Below the operating profit line, our adjusted interest expense declined 36% driven by our successful debt issuance and tender transactions that we completed last spring and summer. Our adjusted nominal tax rate was 13.6%, lower than we expected, due to increased deductions from the exercise of employee stock options and benefit from finalizing taxes owed on certain returns. As you know, generating strong free cash flow remains a priority across the company, and you are seeing this focus come through in our results. Third-quarter free cash flow was $2.1 billion, up 21% from last year. And year-to-date, free cash flow was $4.9 billion, representing a conversion ratio of 90%, well above our full-year target of 80%-plus.

We remain committed to disciplined capital deployment, balancing investment in R&D and tuck-in acquisitions to drive future growth while returning a minimum of 50% of our annual free cash flow to our shareholders. And year-to-date, we’ve returned $2.8 billion or 57% of the cash we generated, resulting in a total shareholder payout of 51% on adjusted net earnings. Now turning to guidance. For the fourth quarter, we are comfortable with current Street consensus on organic revenue growth and EPS prior to any impact from the coronavirus. We expect overall organic top-line growth of approximately four and a half percent.

By group, we expect CVG to grow four and a quarter to four and a half perent; MITG, six and a quarter to six and a quarter percent; RTG, approximately 4% organic; and diabetes to be flat to down low single digits. And based on recent rates, currency would have a negative impact of 80 to 140 basis points. On margins, we continue to expect our full-year operating margin to expand by roughly 40 basis points on a constant-currency basis driven by our enterprise excellence initiatives.

For the fourth quarter, we expect our operating margin to be up slightly including the impact of currency or roughly flat on a constant-currency basis as we invest to support current and upcoming product launches. Below the operating line, we expect our fourth-quarter interest expense to be approximately $160 million to $165 million and our fourth-quarter adjusted nominal tax rate to be around 16% which would put our annual rate at approximately 15%, lower than we originally expected and reflecting the benefits we have had so far this year.

We are raising our fiscal year ’20 EPS guidance to a range of $5.63 to $5.65, up from $5.57 to $5.63 and reflecting our third quarter bottom line outperformance. For the fourth quarter we expect a $1.62 to a $1.64. As mentioned upfront all of the guidance I just gave excludes the impact of the coronavirus, because the situation is so fluid it is difficult to truly quantify the impact just a few weeks into our quarter and for that reason we plan to provide an update for you later this quarter. Finally, I would like to note that we plan to hold our Biennial Institutional Investor and Analyst Day on Tuesday June 2nd in New York City.

Back to you Omar.

Omar Ishrak — Chairman and Chief Executive Officer

Thanks, Karen. Id now like Geoff to make some remarks in the quarter and the outlook. Geoff?

Geoffrey S. Martha — President

Thank you, Omar. There are a number of positive things from the quarter that I want to highlight. But first I’d like to address our top line performance. Even though much of it was transient we did not perform at the level we were expecting and the drivers surfaced at the end of the quarter. We just can’t have surprises like this, for us nor for you. And we are making changes. At our upcoming Investor Day in June, I’m going to walk you through what innovation driven growth means for Medtronic and a comprehensive set of initiatives to take full advantage of the pipeline. These initiatives are meant to ensure we see the acceleration of our revenue from the pipeline and to improve our predictability.

On that note, I want to discuss an aspect of our plan to address the surprise we saw this quarter. One issue is the weighting of our revenue to the final month of the quarter, which leaves us susceptible to surprises late in the game like what happened this quarter. Too often our largest orders come in at the end of the month. This dynamic makes the business challenging to manage, it stresses our operations and it really makes it difficult to mitigate headwinds that pop up within the quarter. So to fix this, we will change our current operating mechanisms, certain internal metrics and some incentives as well. And I want to flag the opportunity coming up with our extra week in Q1.

The impact of the changes that I just mentioned likely won’t be contained in a given quarter. So I’d like to use a good portion of the benefit that we would get from the extra week in Q1 to launch these initiatives. So when we guide to the first quarter we will give you guidance on an underlying basis, excluding the benefit of the extra week. And we’ll give you an estimate of the benefit of the extra week net of these changes. Like I said, we plan to discuss these and other changes during our Investor Day. But I want to assure you one thing that I’m on this and we are taking the appropriate actions to improve consistency and avoid future surprises.

Now before I close and we get to Q&A, I’ve got to highlight a number of good things that occurred this quarter. Accomplishments that I believe can’t get lost in this quarter’s narrative. First we drove a better operating margin despite the light top line and free cash flow was outstanding. These are two things that we’ve been working on for a long time. Over the past couple of years, we’ve taken action on both of these areas and we feel really good about the operating rigor and the culture we’ve put in place to drive the bottom line and improve cash flow.

Also emerging markets growth continues to be strong for us. They represented 17% of our revenue and once again grew strong double digits, 14% this quarter. We think of emerging markets actually as an independent growth factor for the company and we have to acknowledge the progress with our pipeline. We are starting to see approvals and launches come through for important and innovative products and there’s more to come. Yes, the slowed purchasing ahead of these launches hurt us in some businesses this quarter, but this is going to turn. Customers are really excited about our new offerings. I like to end by saying that the underlying fundamentals of the business are strong.

We have a full pipeline that will accelerate our revenue growth and take share not just next quarter but next year and beyond. We’re very excited about the future of the company. The new technology that we’re bringing to market, the impact this will have on patients and physicians and the value we’re going to bring and generate for our shareholders.

All right, back to you Omar.

Omar Ishrak — Chairman and Chief Executive Officer

Thanks, Geoff. I couldn’t agree more with the approach that we are taking, and I’m just as excited about our outlook going forward. Before we start Q&A, I’d like to briefly note that we currently anticipate holding our Q4 earnings call which will be my last earnings call on Thursday May the 21st. Let’s now move on to Q&A, in addition to Karen, Geoff and me our four group Presidents, Mike Coyle, Bob White, Brett Wall and Sean Salmon, are also here to answer your questions.

As usual we want to try to get to as many questions as possible, so please help us by limiting yourself to one question and if necessary a related follow up. If you have additional questions please contact Ryan and our Investor Relations team after the call. Operator first question please?

Questions and Answers:

Operator

Your first question comes from the line of Bob Hopkins with Bank of America.

Bob Hopkins — Bank of America — Analyst

Thank you and good morning. Just I’ll state both questions upfront to make it easy. First, I was wondering, in CVG, if we could drill down a little bit on ICDs given the weakness in the quarter and I ask because you know Boston Scientific also saw weakness in the quarter in their high power ICD business and the timing of your new launch you shouldn’t really be a surprise.

So I guess my first question is how can you have confidence that this isn’t just a slower market? So that’s question number one. And then the thing I also love a quick comment on is that, I realize it’s too early for formal fiscal 2021 guidance, but you guys have talked a lot about accelerating growth in fiscal 2021, so are you still comfortable accelerating off of that 4.5% that we’ll see hopefully in the fourth quarter on the same selling day basis? Thank you.

Omar Ishrak — Chairman and Chief Executive Officer

Thanks, Bob. Mike Coyle is the right person to address the ICD questions. Go ahead, Mike.

Michael J. Coyle — Executive Vice President and Group President, Cardiac and Vascular Group

Yeah, we’re not seeing anything that would cause us to have a concern that the overall market for ICD is somehow slowing significantly. Most of the challenges that we have in ICDs remain the issue associated with the replacement cycle and the fact that we were seeing essentially mid teens declines in year-over-year comparisons on replacement. As I’ve mentioned before that actually gets better as we get through the year and into next year, especially in the CRT-D area. And that is going to help us in terms of acceleration the ICD side. But the other point and you pointed out the surprise to us in terms of weakness in the number for the quarter was really in EMEA, in Europe and Middle East and Africa.

That was where essentially we believe customers were holding off given the imminent launch of our Cobalt and Crome product families which now have launched into the market. And those products will be coming to the United States during the first quarter. The other thing that depressed the overall performance relative to where we thought we would be during the quarter is the fact that the TYRX anti-infective envelopes get captured under the ICD numbers when we report externally. And I think you may recall last quarter we had a fairly major you know, quality driven back order situation that we expected would be resolved completely during the course of Q3. We actually lost a number of — lots of product manufacturing, lots of product early in the quarter which now has stabilized.

In fact, through the second half we’re completely out of any kind of constraints on supply. So we expect that will flow through into the numbers in Q4 and obviously into next year, especially as we have new data that we’ll be presenting at ACC on risk stratification for TYRX. So we think all of those things are going to help us accelerate the ICD market not only in Q4 but into next year.

Omar Ishrak — Chairman and Chief Executive Officer

Okay, thanks, Mike. I think, Karen, you’re the best person to take the question.

Karen L. Parkhill — Executive Vice President and Chief Financial Officer

Yeah. Thanks for the question on ’21 Bob. Yeah, we’re excited about our pipeline and what it has to offer for FY ’21. I’d love to talk a lot about it, but we’re close to finalizing our plan, so we’ll give the official guidance on our Q4 call as you know. That said, I would think about accelerating growth for next year off of a full year basis as opposed to off of a sequential basis. And we’re very confident in our growth acceleration of FY ’21 over FY ’20.

Ryan Weispfenning — Vice President, Head of Investor Relations

Okay, thanks, Bob. Next question please?

Operator

Your next question comes from the line of David Lewis with Morgan Stanley.

David Lewis — Morgan Stanley — Analyst

Good morning. Just — maybe just one quick question for me here. Karen just to confirm for your last question is the right way to think about fiscal 20, I’m assuming a sort of 3.5% to 4%, but my one question I’ll keep it to one is just to give a 4Q guidance I appreciate it’s in line with consensus, but I think about Omar and Geoff’s comments about RTG and CVG, it seems like the 3Q dynamics getting better into the fourth. Shouldn’t the fourth quarter be stronger as we see some of this catch up revenues? If you just help us quantify the third quarter issues and offer some clarity what fourth quarter implies in terms of recovery and drivers of acceleration. Thanks so much.

Karen L. Parkhill — Executive Vice President and Chief Financial Officer

So let me take the beginning of it and then I’ll let my colleague jump in too. So in terms of FY ’20 that our fourth quarter guidance would imply FY ’20 growth of 3.6%, 3.7%-ish. And then on fourth quarter clearly because of the transient issues in the third quarter we expect some of that to come back.You know if you look at MITG and the ERP issues that we’ve talked about, we fully expect that to come back. And that’s one of the reasons that we’ve guided MITG to you know above trend for the quarter. That we have lost some procedures, and those won’t come back.

Omar Ishrak — Chairman and Chief Executive Officer

I think I don’t know if I can add anything to that. You know, really the procedure losses in a business like MITG where the procedures happened that just isn’t going to come back, will recover fully. I think in other areas like in the MCS business or LVAD business you know, that was share loss and there’s pressure there and our growth is probably going to be lower than we were originally anticipating.

So in balance we felt that holding the Q4 sort of previous guidance was the appropriate thing to do at this stage. We’re obviously doing everything we can do to maximize that number.

Ryan Weispfenning — Vice President, Head of Investor Relations

Okay, thank you, David. Next question please?

Operator

Your next question comes from the line of Robbie Marcus with JP Morgan.

Robbie Marcus — JP Morgan — Analyst

Thanks for taking the question. Maybe if we could shift to some of the product lines and specifically TAVR here, 13% worldwide growth, came in a lot lower than The Street was expecting. You had the first full quarter of the low-risk launch in the U.S. Your competitor did a lot better than this.

Maybe talk to exactly what happened in the quarter, the dynamics in the U.S. and how you expect this continue throughout fourth quarter and ’21. Thanks.

Omar Ishrak — Chairman and Chief Executive Officer

Mike, do you want to take that?

Michael J. Coyle — Executive Vice President and Group President, Cardiac and Vascular Group

Yes. Robbie obviously, we were very disappointed with the performance in the U.S. If you look outside the U.S., we — the implant growth rates were in the high teens and pretty much in line with the overall market, actually a little better than the overall market because of the Japan influence, but in the United States, obviously well below market with implant rates in the mid-teens, whereas we would estimate the market in the quarter probably grew on the order of the low 30s. As we dug into that, we obviously headed into the holidays actually feeling pretty good that we were looking at implant rates in the low 20s.

Obviously, in retrospect, that turns out to be lower than the market. But as we headed into the end of the year and into January, we saw a pretty meaningful decline in overall growth rates for implants, and we dug deeply into that to figure out which accounts and where we were having the issues. And basically, I think learning from that analysis was that it takes longer than we thought to have our reps become fully competitive in this market. It’s probably a nine to 12 month training exercise which, in retrospect, we probably should have ramped up in advance of this several quarters earlier than we did.

The good news is that as we look at the hiring that we did do, this quarter, we expect to bring on 70 new sales reps and support personnel which is going to help us go from — given the 700 accounts that are selling ICD or selling — that are servicing this market, we probably have seasoned sales reps, that is those who have a year or more experience in about two-thirds of those accounts. By the time we exit with these new certifications, we would expect to be closer to 80% in terms of supporting that. And we’re also accelerating new hiring based on driving support for our next fiscal year. So we think those just catch up in terms of training and deployment.

Plus we’re pushing much more closed interval management of the reps that are out there to make sure that we’re staying on top of developments in these accounts. We think that, coupled with, obviously, our new product launch around Evolut PRO+, the launch of the Confida sheath which really improves the performance of our overall device systems and then new data that will be coming out here at ACC around both bicuspid and leaflet immobility, should basically give us an opportunity to accelerate from where we were in Q4 — or in Q3. And basically, looking at just the daily sales rates here as we’ve headed into the new quarter with this new focus on rep productivity, we are seeing some acceleration from those numbers that you see in terms of the mid-teens implant rates. And so I’m confident we’re going to see acceleration.

Whether we’ll get all the way back to market, given that we have two competitors who are driving share in those accounts, it may take more than a quarter to do that. But on the other hand, I do expect to see acceleration during the quarter.

Robbie Marcus — JP Morgan — Analyst

Thanks.

Ryan Weispfenning — Vice President, Head of Investor Relations

Okay, thank you, Robbie. Next question please.

Operator

Your next question comes from the line of Vijay Kumar with Evercore.

Vijay Kumar — Evercore — Analyst

Hi, guys. Thanks for taking my question. I had two quick ones. One, Surgical Robotics, I think you mentioned some software updates just on time line there, you know, MITG, you have sequential acceleration. Is there anything baked on the robotic side there?

And second, on margins. I appreciate the comments on you know, FX hedge gains you know, when you look at next year I think Geoff made some comments and changing incentives, so maybe just talk about margins for next year, are we still looking at in a constant currency you know, in the 40 to 50 basis points of expansion? Thank you.

Omar Ishrak — Chairman and Chief Executive Officer

Okay. Let me — Bob, will probably answer this. But you know, I’ll just say off the bat that robotics is not in our financial numbers yet, and the overall program is more or less on track. So —

Robert White — Executive Vice President and President, Minimally Invasive Therapies Group

That’s right, Omar. Thanks, Vijay for the question. To reiterate, first off, no updates from what we talked about at JPMorgan relative to the program, so it’s just good news. And then the sequential acceleration of MITGs business is really all about us coming out of the ERP implementation, now that we’ve got that back on track and the system is running smoothly. So I hope that does it for you Vijay.

Vijay Kumar — Evercore — Analyst

And then on the margins guys?

Karen L. Parkhill — Executive Vice President and Chief Financial Officer

Thanks, Vijay. On margins for next year, we’re going to continue to look at margin expansion, as we drive bottom line growth about top line growth every year. At this stage we haven’t changed our long range guidance of 40 basis points constant currency margin expansion. So you can assume that at this stage.

Vijay Kumar — Evercore — Analyst

Thanks, guys.

Omar Ishrak — Chairman and Chief Executive Officer

I can tell you Vijay, there is a focus in the organization around that. We’ve worked very hard to get a — an accountability around that. And you know, we’re going to — you’re going to – that’s going to stay. We just need to fix our top line growth back to where it deserves to be based on our product pipeline.

Vijay Kumar — Evercore — Analyst

Appreciate the comments Omar.

Omar Ishrak — Chairman and Chief Executive Officer

Okay. Thanks, Vijay.

Ryan Weispfenning — Vice President, Head of Investor Relations

Next question please?

Operator

Your next question comes from the line of Matt Taylor with UBS.

Matt Taylor — UBS — Analyst

Hi, thank you for taking the question. So the first one I want to ask was just on MITG ERP transition. I was wondering if that impacted any of the business lines within MITG more than the others. And are you seeing underlying share loss there. Or share gains. Can you talk about the underlying trends?

Omar Ishrak — Chairman and Chief Executive Officer

Go ahead.

Robert White — Executive Vice President and President, Minimally Invasive Therapies Group

Yes, let me take that Omar. Matt, thanks for the question. The impact of the ERP transition affected all of the MITG product lines as we migrated into the single SAP system for Medtronic. And you know certainly we lost some procedures where we weren’t able to ship products to customers.

So while we think we lost procedures given the middle months of the quarter, we don’t believe we necessarily lost a significant amounts of share. But certainly now that we’re back on track with ERP system we’re back to fulfilling those customer requirements.

Matt Taylor — UBS — Analyst

Thanks. Just a follow for Mike or the team there. So it sounds like you’re seeing a little bit of an improvement in the DCB trends at least in the U.S. Could you speak to that and whether you think we could see any kind of continued uptick there or a change in the FDA stance at some point during the year?

Omar Ishrak — Chairman and Chief Executive Officer

Go ahead, Mike.

Michael J. Coyle — Executive Vice President and Group President, Cardiac and Vascular Group

Sure. We are seeing some modest improvement obviously as more data sets come in, they are providing more comfort to physicians and FDA for that matter I believe, that the signal that had been observed in those first three randomized trials around SFA seem not consistent with the new data coming in.

Obviously one big dataset that we filed and got approval for was the AV fistula indication for DCB, which did not show this mortality signal in the paclitaxel arm. And we expect additional data to be coming out on that topic, including at the ACC where we think there’ll be a presentation of a major data set based on claims, analysis.

So that is creating a greater sense of confidence in the physician base that the significant morbidity issues that come with not using these drug-coated balloons and just using PTA balloons are beginning to get attention. And I think what we expect to see is continued improvement as data sets provide that — that level of comfort.

So in this quarter we did see, on sort of selling day adjusted basis some sequential growth which is encouraging in the DCB and we expect if the data continue to come in as positive as they have that we’ll see that continue.

Matt Taylor — UBS — Analyst

Thank you, Mike.

Ryan Weispfenning — Vice President, Head of Investor Relations

Thanks, Matt. Next question please?

Operator

Your next question comes from the line of Kristen Stewart with Barclays.

Kristen Stewart — Barclays — Analyst

Hi, thanks for taking my question. I just wanted to ask Sean if he could just provide his overall thoughts on diabetes since he’s kind of taken over the role and then if we could just kind of get an update on 780G. It sounds like that is getting pushed a little in the U.S.

Into next fiscal year. Maybe just some thoughts around the timeline there. Thanks.

Michael J. Coyle — Executive Vice President and Group President, Cardiac and Vascular Group

Sure, thanks, Kristen. So as you know, the diabetes business certainly has no small challenges to overcome. But I can tell you I’m really very encouraged with how we’re seeing some derisking of the pipeline that we have going forward.

In particular, that sensor pipeline, I’m convinced that we’ve figured that out, and it’s just a bit of time for us to get the product line flowing there. The 780G is an important catalyst for us to drive growth, and we expect that to begin. We have filed the CE mark for that device, and we are anticipating, as Omar said, putting the clinical data module in, in the March time frame. That review is going well.

We’re very interactive with FDA. In fact, we’ll be meeting with them later this week. And we’ll give more update on exactly what the timing is as we get more information on it. So far, we’re happy with what we’re seeing both from the algorithms, and you’ll see some of that later this week as we stress the algorithm into some challenging conditions that will be announced at ATTD.

And the data front, and you’ll see the full dataset coming up at the ADA in June. So I’ve seen a lot of encouraging things. There are things to clean up obviously. We’ve got to get the new product flow going, and we’re confident that we’ll be doing that starting soon.

Kristen Stewart — Barclays — Analyst

And then just your comments around the derisking, particularly around the sensors, can you maybe just expand upon that? Do you think there’s an opportunity to bring forward some of the sensor timelines?

Michael J. Coyle — Executive Vice President and Group President, Cardiac and Vascular Group

Kristen, I think the first thing is to meet the criteria for iCGM, and I’m confident that we’re going to be able to demonstrate that. We’ll have more information on that in the coming meeting. But probably at analyst day, we’ll show you some more of that. It’s too early to comment on accelerated timing, but that’s certainly the goal, to push as fast as we can into the marketplace.

Kristen Stewart — Barclays — Analyst

Perfect, thanks.

Ryan Weispfenning — Vice President, Head of Investor Relations

Thank you, Kristen. Next question please.

Operator

Your next question comes from the line of Kaila Krum with SunTrust.

Kaila Krum — SunTrust — Analyst

Thanks, guys. Thanks for taking our questions. So one quick one to clarify and then a question on the business. So on the coronavirus, I think you may have mentioned this but again just to clarify. Will you give full transparency on your China business performance in the fourth quarter?

Karen L. Parkhill — Executive Vice President and Chief Financial Officer

Yes, we will. And we do disclose our growth rate in China already. So we will we will continue to disclose that. We will be transparent about the impact of the coronavirus.

Kaila Krum — SunTrust — Analyst

Perfect. And then there’s obviously a lot of new product launches coming in the next few quarters. But I mean obviously it can be challenging to predict that the timing and the impact of when those new launches contribute. So I’m just curious how you’re modeling your product contribution in the fourth quarter and as part of that re acceleration in the business? Thank you.

Omar Ishrak — Chairman and Chief Executive Officer

Well there are some that are pretty clear, things like the Micra AV, which launched last quarter is now in full steam and moving ahead well, and that one you know we’re projecting a strong success.

There are others like the in the spinal cord stimulation market, we just launched the Stimgenics waveform on the Intellis platform. That’s picking up. That you know, we were a little more guarded about that because that’s newer. But for sure that’s going to help us in the spinal cord stimulation market.

Things like Cobalt and Crome in Europe, again, we have a history there and we can — we can project historically what such that kind of improvement has caused and where we’re going to put that into a model. So you know there’s a mix of the level of you know sort of confidence intervals we have in these projections some very tight and you know Micra being one of the biggest drivers is very tight. The other is a little more unknown but positive nonetheless. I think that’s the best I can do — or anyone else here, any products I’ve missed or any comments, you guys?

Brett Wall — Executive Vice President and President, Restorative Therapies Group

We’ve recently launched the Micro which is the new public health product in Europe which you know we’re excited about that and the possibility for that looking to late spring launch in the United States. And then Percept, which is the new DBS with brain sensor technology has just launched in Europe. Similar timeframes in the U.S. approval and we’re getting good uptake on that. So those are two very interesting platforms for us in the neuromodulation space.

Michael J. Coyle — Executive Vice President and Group President, Cardiac and Vascular Group

And the other thing I would mention is the DiamondTemp ablation catheter CE mark that we expect during the quarter which would obviously be even more of a benefit in Q1 of next year, as well as we’re just in the early stages of the launch of the AV fistula indication for the IN.PACT Admiral balloon, so those will now get full quarter benefit during Q4.

Omar Ishrak — Chairman and Chief Executive Officer

I think to your question about how we project these you know, there’s a historical sort of comparison that we can make against similar such launches and based on that we make a judgment in our in our planning and from that we derive guidance and our plan going forward. So there’s a variety of that, but you know there’s some judgment involved with this.

Kaila Krum — SunTrust — Analyst

Thanks, guys.

Ryan Weispfenning — Vice President, Head of Investor Relations

Thank you, Kaila. Next question please.

Operator

Your next question comes from the line of Larry Biegelsen with Wells Fargo.

Larry Biegelsen — Wells Fargo — Analyst

Good morning, thanks for taking the question. Mike, could you please put a finer point on the launch timing of that Cobalt and Crome in the U.S. and LINQ 2.0. What quarter are you expecting it. And Brett, on SNM, what are you seeing – for sacral neuromodulation, what are you seeing from the new competitor and what are your expectations for that business before micro is approved in the U.S. in late spring which I heard you say a minute ago. Thanks for taking the questions guys.

Michael J. Coyle — Executive Vice President and Group President, Cardiac and Vascular Group

So Larry on Cobalt and Crome, we would expect that in the first quarter of next year probably in the first half of that quarter and then for LINQ 2.0 we would expect that product also in Q1 but in the second half of the quarter.

Brett Wall — Executive Vice President and President, Restorative Therapies Group

Yes, then Larry on public health and on the Micro I think we you know expect some near-term slowing here with that particular product given the competition, the Micro itself in Europe has been received very well, just as a reminder it’s about half the size of the competitive device, the recharge experiences significantly better and with the SureScan leads, leads, it is 1.5 and 3 Tesla full body conditional. So we’re very, very excited about that product when it comes to the market in United States.

Larry Biegelsen — Wells Fargo — Analyst

Thank you.

Ryan Weispfenning — Vice President, Head of Investor Relations

Thank you, Larry. Next question please.

Operator

Your next question comes from the line of Matt Miksic with Credit Suisse.

Matt Miksic — Credit Suisse — Analyst

Hi, thanks for taking the question. So I just have one on coronavirus and one on sort of the Symplicity Spyral timeline and post the data at ACC. So on corona, I understand it’s a little bit early to put a finer point on the impact for Q4, but if you could maybe give us some sense of what the major moving parts are.

I think we have about $2 billion in China revenue round numbers, an approximately kind of an annual run rate there. Obviously, it’s a moving target, but things like — would an impact in Q4 likely, based on what you know now, sort of come back in early — how transitory is that impact? And then on Spyral, just maybe walk through for us the timeline of what happens after off med and what that looks like as you continue to develop that program.

Omar Ishrak — Chairman and Chief Executive Officer

Okay. Let me take the coronavirus question first. First of all, we’re pretty clear about what our China business is. It’s roughly 7% of our global business, so you can do the estimate there.

The variables right now — one variable is that we’ve got to get our factories up and running so that we can supply different places in the world including China, and that is actually progressing well. But the main factor driving the number there will be the procedure uptake in China. China was in a complete shutdown mode for the first half of February, and they’re just beginning to start. And even now, even in places like Beijing and others, procedures are only just beginning.

It’s too early to tell how they will ramp up through the rest of the quarter. We know that in Hubei province, for example, obviously, it shut down, but that’s only 5% of China. But the rest of China, in places like Beijing and Shanghai, right now, there are procedure delays. In addition to that, a lot of physicians are being asked to actually go and help with the virus.

And so there are many dynamics here that are really difficult to predict now.

Once things stabilize, there could well be a ramp back up. And because people need the procedures, they will get them at some point. When that happens is very difficult to predict right now.

So that’s why we’re saying that wait until a little later in the quarter when we have some more data and see how things progress and we’ll give you a full update. So with that, I’m going to ask Mike to take the renal.

Michael J. Coyle — Executive Vice President and Group President, Cardiac and Vascular Group

So our renal denervation, obviously, the first big milestone will be the pivotal trial on the off med which will be presented here at ACC. But there is the second trial that is ongoing in parallel which is the on med trial. Unlike the off med, it has a six-month efficacy endpoint. So if I were to set expectations for when those data were to become available, I would expect that about a year from now, so about this time next year.

In terms of the FDA interaction, the on med — or the off med data will be used in a modular submission as we — along with, obviously, the device-supporting materials. So we think we can get the process with FDA to move forward.

We do think we need the off med — or excuse me, the on med dataset in order to get final approval for the product, and certainly, it will be very important in terms of reimbursement to have those data. So that would be how I would set expectations.

Obviously, I think you know the Spyral product is available in Europe currently. It does have CE mark. So as these datasets become available, customers can evaluate them and decide how they want to use that product.

Matt Miksic — Credit Suisse — Analyst

Great. Thank you.

Ryan Weispfenning — Vice President, Head of Investor Relations

Thank you. Next question please.

Operator

Your next question comes from the line of Chris Pasquale with Guggenheim.

Chris Pasquale — Guggenheim — Analyst

Thanks. Mike, I just want to circle back on the 4Q CVG growth outlook. It sounds like some of the headwinds there like LVADs and TAVR may take at least another quarter to address. I’d imagine that there’s potentially some risk that U.S. ICD growth slows ahead of those launches just like we saw in Europe. So Micra AV should help, there’s a couple of things that go your way which is the confidence in driving that acceleration in the fourth quarter? Thanks.

Michael J. Coyle — Executive Vice President and Group President, Cardiac and Vascular Group

Sure. I think as you point out you know, we have lowered our expectations for the LVAD numbers just based on you know not seeing the sequential share capture in Q3 that we had seen in Q2. You know, it’s some competitive indications approvals. But on the other hand you know obviously we got the Micro AV early in terms of you know we expected that it would be later in the quarter when we were setting guidance last quarter and the customer response has been strong in terms of interest in the technology.

And as a reminder this is a product that carries a 3 times price uplift relative to a standard dual chamber system and our indications for use cover all AV patients. So we expect that an opportunity to drive this product meaningfully into the market above what we were thinking a quarter ago when we were giving guidance for Q4.

In addition although obviously the Cobalt and Crome products won’t be in the US they will be in Europe. And so unlike last quarter where we really had no meaningful new products and we saw the customers pausing and while waiting for new products. Now we have a number of new products globally that are obviously going to make a difference for us. And so net, net we’re pretty much holding our expectations for growth where we were a quarter ago despite the moving pieces in this quarter.

Chris Pasquale — Guggenheim — Analyst

And does the guidance contemplate a pause in U.S. I see the orders ahead of those launches?

Michael J. Coyle — Executive Vice President and Group President, Cardiac and Vascular Group

It certainly shows no meaningful acceleration in those – in those numbers, so its something along the lines of what we’ve had. And as I said we’re also seeing some improvement in the replacement cycle generally because of the CRT-D side of things.

And the other thing I should mention is obviously we will anniversary in March the paclitaxel issue, which was a big step down in the prior year quarter which gives us just an easier comp to work with as we’ve seen sequential growth on a selling base basis the last couple of quarters in DCB.

Chris Pasquale — Guggenheim — Analyst

Thanks.

Omar Ishrak — Chairman and Chief Executive Officer

I don’t disagree that TYRX, although we won’t get to share capture this quickly. We certainly have sequential growth.

Michael J. Coyle — Executive Vice President and Group President, Cardiac and Vascular Group

Absolutely. That we were constrained for more than half of last quarter in terms of supply and now we are essentially unconstrained. And in addition, we are expecting to get labeling expansion to one year dating on that product in the United States which will help us significantly in terms of just the logistics of its growth.

Ryan Weispfenning — Vice President, Head of Investor Relations

Thanks, Chris. Next question please.

Operator

Your next question comes from the line of Pito Chickering with Deutsche Bank.

Pito Chickering — Deutsche Bank — Analyst

Good morning and thanks for taking my question. To follow up on Robbie’s question on U.S. TAVR. I understand the sales rep issues are holding back growth of new accounts.

But are the sales reps really holding back growth in established accounts? Is that where the growth is falling? Is it from the new accounts or from the established accounts? Thanks so much.

Michael J. Coyle — Executive Vice President and Group President, Cardiac and Vascular Group

Yes. It’s a great question. Actually, what happened was there was a tremendous focus on launching the Evolut PRO+ as well as opening up the NCD accounts. And what we wound up doing because of the relative immaturity of a good bit of our field force is pulling reps who are supporting large accounts to help with that expansion into new accounts.

And obviously, with a new competitor entering the market and some complex messaging having to come in as low-risk patients were approved, it just proved to be too much. We were spreading our field too thin. And so obviously, we’ve refocused back into those large accounts to make sure that our messaging around improved hemodynamics, the benefits of the Evolut PRO+ in terms of both profile and now adding the pericardial wrap into the large device segment and then, obviously, just selling the benefits of the hemodynamic data that was presented at ACC a year ago. Those are things now that we believe are helping to show this acceleration in growth that I referenced as we head into this quarter versus where we were in January.

Ryan Weispfenning — Vice President, Head of Investor Relations

Thanks, Pito. Next question please.

Operator

Your next question comes from the line of Matthew O’Brien with Piper Sandler.

Matthew O’Brien — Piper Sandler — Analyst

Good morning. Thanks for taking my question. I’ll just stick with one. Geoff, I appreciate you don’t want to say much about this new program that you’re going to implement until investor day in June, but we’ve seen contract manufacturers do something like this before, but never really a manufacturing company do something like this.

So can you just talk about the potential economic impacts to Medtronic? I mean do you have the scale to kind of work through some of these things on the top line? Is there going to be better pricing so there could be a little bit of gross margin pressure longer term, so there’s some free cash flow impacts here? So just how do we think about some of the puts and takes here of this new program?

Geoffrey S. Martha — President

Yeah. Well, look, I didn’t — just one clarification on what I spoke about. I think this is the second question around will some of these changes impact our margins. And the answer to that is no, right? We’re talking about focus on increasing our revenue and the overall revenue growth as well as the consistency and predictability of that revenue growth, but we don’t want to take a step back on the margin improvement that we’ve built up and the cash flow conversion improvements that we had done over the last couple of years as a result of our — these are sustainable changes from our enterprise excellence program so we don’t want to take a step back on that.

What I mentioned this morning — on this morning’s call was the very specific changes that we want to make to improve orders that are coming in late in the quarter. We have a couple of our larger orders, some of our — coming in late in the quarter which stresses our system, and we’ve got to execute better really to get those in earlier. We’re putting too much pressure on the last month, and that’s specifically what I spoke of this morning. And when I hinted at for investor day was more on what are we doing to realize the full benefits of the pipeline.

Look, like the fundamentals of the business are strong. What I mean by that specifically, you guys know the markets are doing well, we have good market share positions. But more importantly in terms of momentum, the product pipeline is coming to fruition here. So we need to make sure that we put the right programs in place to realize the full benefits of that pipeline around commercial execution.

So that’s — we’ll get into more of that on investor day. What I talked about this morning was more having a regular — moving some of our back-end loading of our quarter and spreading that more evenly throughout the quarter, but nothing regarding — nothing changed regarding margin.

Matthew O’Brien — Piper Sandler — Analyst

Thank you.

Ryan Weispfenning — Vice President, Head of Investor Relations

All right. Thanks, Matt. I think we’ve got time for one more question. Please operator.

Operator

Our final question will come from the line of Josh Jennings with Cowen.

Josh Jennings — Cowen — Analyst

Hi, good morning. Thanks for taking the questions. Just two questions for Karen on margins. Just on the gross margin pressure you’ve experienced so far in fiscal ’20. Can use to help us understand the drivers of that. And is this and it’s sub 70% level the new normal? Or is there a recovery path? And has it been FX, pricing pressure, mix shift?

And then just on the other income tailwind that you’ve experienced in fiscal ’20 outside of FX hedging can you talk about the drivers of that benefit and then how sustainable and predictable that line item will be going forward? Thanks for taking the questions.

Karen L. Parkhill — Executive Vice President and Chief Financial Officer

Yeah. Thank you, Josh. No problem. So on gross margin one of the larger prices that we’ve had on gross margin is the increase in China tariff. And as long as they stay that will be a continued pressure.

Gross margin is obviously impacted by mix and as we introduce some of our key new products that should help gross margins going forward. And as we think about the net other expense or income line item, we had a benefit this quarter that was primarily driven by a swap program that we have in place to hedge the gains and losses that are part of our deferred compensation program and SG&A. And so that was really driven that. Our SG&A line would have been even better if it didn’t have a loss that we effectively offset by a gain in net other.

Josh Jennings — Cowen — Analyst

Thank you.

Ryan Weispfenning — Vice President, Head of Investor Relations

Thank you, Josh. Omar, do you want to wrap up?

Omar Ishrak — Chairman and Chief Executive Officer

Yeah. Well, thank you all for your questions and behalf of the entire management team, I’d like to thank you again for your continued support and interest in Medtronic. Look we’ll get this thing right. We’ve got a task to do here, we’ll get acceleration growth profile in Q4 and that will continue into FY ’21. Our product pipeline is strong and this team is committed behind it, we couldn’t have — I couldn’t have asked better team and more committed and we’ll get this thing right, I assure you. And then we really look forward to updating you on our progress on our Q4 earnings call. Thank you.

Operator

[Operator Closing Remarks]